AbbVie (ABBV)

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells.

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Here's why the 90-day tariffs delay doesn't help pharmaceutical companies.

Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence.

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.

Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.

Wall Street saw a tentative tech rebound early Wednesday, as investors begin to shrug off escalating U.S.-China trade tensions following a steep market selloff.

The US market session of Wednesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.

ABBV is currently showing a pronounced move down in both daily and 1-hour charts, suggesting a deeper ZigZag correction in play.

President Donald Trump on Wednesday announced a slew of tougher-than-anticipated tariffs, but there are some notable exemptions to the steep levies. Here's a look at which products and sectors are excluded from the reciprocal tariffs:

It's unclear whether pharmaceutical goods could be exempt from tariffs. A number of drugmakers manufacture ingredients abroad.

Markets got a double dose of bad news about inflation and consumer confidence; next week, the Trump tariffs and Jobs report are likely to keep volatility high